TILT is open to collaborations with pharmaceutical companies, specifically in the context of enhancing the therapeutic efficacy of cancer immunotherapies in development by stimulating T cells.
We are also looking to explore licensing agreements to support the commercialization of our pipeline.
Our current partners
The company’s technology has been validated through several commercial partnerships, including ones with Germany’s Merck, Pfizer, and with Biotheus for TILT-123’s development in Greater China.
TILT also has an academic collaboration in the US with the University of Pennsylvania, exploring the use of TILT-123, combined with CAR-T, in solid tumors, as well as the Cancer Gene Therapy Group at the University of Helsinki.
If you are interested in discussing partnering opportunities with TILT then please contact: